Index S&P 500
P/E 15.32
EPS (ttm) 25.61
Insider Own 0.21%
Shs Outstand 231.92M
Perf Week -0.87%
Market Cap 90.97B
Forward P/E 10.04
EPS next Y 39.05
Insider Trans -1.50%
Shs Float 231.43M
Perf Month 3.02%
Income 5.98B
PEG 1.40
EPS next Q 10.62
Inst Own 90.01%
Short Float 1.26%
Perf Quarter -6.11%
Sales 176.81B
P/S 0.51
EPS this Y 4.42%
Inst Trans -1.30%
Short Ratio 1.59
Perf Half Y -24.73%
Book/sh 188.74
P/B 2.08
EPS next Y 13.20%
ROA 5.30%
Short Interest 2.91M
Perf Year -20.57%
Cash/sh -
P/C -
EPS next 5Y 10.92%
ROE 14.83%
52W Range 362.21 - 567.26
Perf YTD 6.33%
Dividend Est. 6.82 (1.74%)
P/FCF 19.99
EPS past 5Y 6.81%
ROI 8.48%
52W High -30.85%
Beta 0.87
Dividend TTM 6.52 (1.66%)
Quick Ratio -
Sales past 5Y 11.25%
Gross Margin -
52W Low 8.29%
ATR (14) 9.64
Dividend Ex-Date Mar 10, 2025
Current Ratio 1.45
EPS Y/Y TTM 7.55%
Oper. Margin 5.03%
RSI (14) 48.74
Volatility 2.42% 2.55%
Employees 104900
Debt/Eq 0.76
Sales Y/Y TTM 3.19%
Profit Margin 3.38%
Recom 1.79
Target Price 481.56
Option/Short Yes / Yes
LT Debt/Eq 0.71
EPS Q/Q -50.18%
Payout 25.39%
Rel Volume 0.39
Prev Close 390.47
Sales Surprise 0.08%
EPS Surprise -4.32%
Sales Q/Q 6.55%
Earnings Jan 23 BMO
Avg Volume 1.83M
Price 392.26
SMA20 -0.91%
SMA50 1.06%
SMA200 -18.20%
Trades
Volume 650,350
Change 0.46%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-22-25 Downgrade
Stephens
Overweight → Equal-Weight
$520 → $440
Oct-18-24 Downgrade
Argus
Buy → Hold
Jul-18-24 Downgrade
BofA Securities
Buy → Neutral
$646 → $530
Jun-24-24 Initiated
Morgan Stanley
Overweight
$643
May-30-24 Initiated
Robert W. Baird
Outperform
$649
Mar-06-24 Initiated
Barclays
Overweight
$584
Jul-12-23 Downgrade
Wolfe Research
Outperform → Peer Perform
Apr-27-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$500 → $571
Apr-21-23 Initiated
Cantor Fitzgerald
Overweight
$547
Mar-28-23 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$523 → $572
Sep-09-22 Upgrade
BofA Securities
Neutral → Buy
$535 → $575
Aug-22-22 Upgrade
SVB Leerink
Mkt Perform → Outperform
$490 → $580
Show Previous Ratings
Jan-31-25 02:59PM
Jan-27-25 07:20PM
Jan-24-25 02:02AM
12:30AM
(Thomson Reuters StreetEvents)
Jan-23-25 04:30PM
(Investor's Business Daily)
01:00PM
Loading…
01:00PM
12:11PM
11:25AM
11:18AM
10:41AM
(Investor's Business Daily)
09:54AM
09:30AM
07:10AM
06:17AM
(Associated Press Finance)
06:00AM
03:42PM
Loading…
Jan-22-25 03:42PM
Jan-21-25 01:44PM
Jan-19-25 05:00AM
Jan-17-25 10:34AM
09:15AM
Jan-16-25 10:54AM
(The Wall Street Journal)
Jan-15-25 08:25AM
Jan-09-25 04:05PM
02:44PM
Jan-07-25 07:57AM
Dec-28-24 04:47PM
Dec-25-24 06:30AM
Dec-24-24 02:00PM
12:20PM
Dec-23-24 05:18PM
01:21PM
Loading…
01:21PM
Dec-20-24 04:57PM
Dec-18-24 12:07PM
Dec-17-24 08:54PM
11:24AM
Dec-11-24 10:54PM
12:19PM
11:40AM
Dec-10-24 09:47AM
Dec-06-24 02:03PM
12:35PM
Dec-05-24 05:10PM
Dec-04-24 01:18PM
Nov-30-24 07:15PM
Nov-26-24 07:30AM
Nov-19-24 06:15AM
Nov-18-24 11:55AM
Nov-06-24 09:45AM
Nov-05-24 04:05PM
Nov-04-24 09:00AM
05:30AM
Oct-28-24 03:51PM
Oct-25-24 10:26AM
(The Wall Street Journal)
Oct-23-24 10:00AM
Oct-19-24 07:00AM
(The Wall Street Journal)
Oct-18-24 04:59PM
12:57PM
03:02AM
01:06AM
(Thomson Reuters StreetEvents)
01:02AM
12:00AM
(Associated Press Finance)
Oct-17-24 07:24PM
(Morningstar Research) -10.59%
07:17PM
07:17PM
05:10PM
03:33PM
03:04PM
(The Wall Street Journal)
01:56PM
01:45PM
01:09PM
12:54PM
12:38PM
12:15PM
11:37AM
11:35AM
(The Wall Street Journal)
10:51AM
10:35AM
09:58AM
09:30AM
08:36AM
07:10AM
06:06AM
(Associated Press Finance)
06:00AM
Oct-16-24 12:10PM
Oct-14-24 09:15AM
08:27AM
Oct-12-24 07:41AM
Oct-10-24 10:00AM
Oct-07-24 03:22PM
10:59AM
08:00AM
06:17AM
Oct-04-24 01:22PM
Oct-02-24 01:00PM
Sep-30-24 10:45AM
Sep-26-24 10:20AM
Sep-25-24 01:49PM
Sep-13-24 05:08AM
Sep-05-24 12:58PM
07:59AM
Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Commercial and Specialty Business, Government Business, CarelonRx, and Other. The Commercial and Specialty Business segment provides insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance. The Government Business segment includes medicare and medicaid businesses, national government services, and services provided to the federal government. The CerelonRx segment offers formulary management, pharmacy networks, prescription drug database, member services, and mail order capabilities. The Other segment is involved in health services business focused on quality of healthcare by enabling and creating new care delivery and payment models. The company was founded in 1944 and is headquartered in Indianapolis, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kendrick Charles Morgan JR EVP & President, Commercial Oct 18 '24 Sale 432.14 7,417 3,205,182 8,423 Oct 18 05:21 PM Kendrick Charles Morgan JR Director Oct 18 '24 Proposed Sale 432.28 7,417 3,206,221 Oct 18 01:48 PM PERU RAMIRO G Director Aug 05 '24 Sale 531.52 753 400,235 8,744 Aug 06 05:23 PM RAMIRO G PERU Director Aug 05 '24 Proposed Sale 531.52 753 400,235 Aug 05 04:14 PM BOUDREAUX GAIL President and CEO Jul 22 '24 Sale 500.98 34,000 17,033,395 126,709 Jul 23 05:02 PM Dixon Robert L JR Director Jul 19 '24 Sale 506.76 305 154,562 9,721 Jul 22 04:30 PM Norwood Felicia F EVP & President,Gov Health Ben Apr 23 '24 Option Exercise 238.27 5,473 1,304,052 45,571 Apr 25 05:05 PM Norwood Felicia F EVP & President,Gov Health Ben Apr 24 '24 Option Exercise 238.27 2,043 486,786 33,503 Apr 25 05:05 PM Norwood Felicia F EVP & President,Gov Health Ben Apr 23 '24 Sale 533.74 14,111 7,531,565 31,460 Apr 25 05:05 PM Norwood Felicia F EVP & President,Gov Health Ben Apr 24 '24 Sale 532.44 6,199 3,300,590 27,304 Apr 25 05:05 PM Kendrick Charles Morgan JR EVP & President, Commercial Mar 08 '24 Sale 500.46 2,432 1,217,119 15,840 Mar 12 04:26 PM Penczek Ronald W CAO & Controller Mar 06 '24 Sale 504.58 916 462,195 1,764 Mar 08 04:16 PM Haytaian Peter D EVP & Pres Carelon & CarelonRx Mar 04 '24 Option Exercise 166.97 15,000 2,504,550 39,982 Mar 05 04:24 PM Haytaian Peter D EVP & Pres Carelon & CarelonRx Mar 04 '24 Sale 500.18 21,095 10,551,297 18,887 Mar 05 04:24 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite